SAM
ACRS icon

Smartleaf Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Smartleaf Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.31K Hold
376
– – ﹤0.01% 3063
2025
Q4 		$1.09K Buy
+376
New +$950 ﹤0.01% 3148

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Smartleaf Asset Management's ACRS Position: Q1 2026 in Review

Smartleaf Asset Management held its Aclaris Therapeutics (ACRS) position steady in Q1 2026 at 376 shares worth $1.31K. The position accounts for ﹤0.01% of the portfolio, ranked #3063.

Smartleaf Asset Management first reported a position in ACRS in Q4 2025 and has held it in 2 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Smartleaf Asset Management held 376 shares of Aclaris Therapeutics worth $1.31K as of Q1 2026.
  • Smartleaf Asset Management left its Aclaris Therapeutics share count unchanged in Q1 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #3063 holding.
  • Smartleaf Asset Management first reported a position in Aclaris Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.